By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


Four Essentials from CTFN this Week

EDP:PL Pre-notification discussions between China Three Gorges and the European Commission with regards to CTG’s acquisition of Energias de Portugal are “quite standard” and take a lot of time generally, a person close to the matter told CTFN. AVA/H:CN Signs have emerged among regulatory agencies in the Pacific Northwest that the pending $5.3 billion merger … Read Morefeatured

Proposed NxStage/Fresenius Settlement Agreement Advanced to Commissioners

A proposed settlement agreement resolving the FTC’s Bureau of Competition’s concerns with Fresenius’s acquisition of NxStage appears to have passed to the commissioner levelfeatured

Five Essentials from CTFN this Week

AET/CVS On the sidelines of the Connecticut Insurance Department Form A hearing regarding CVS Health’s $69 billion acquisition of Aetna, CVS general counsel Tom Moriarty told CTFN the parties are making good progress with the pending antitrust review with the Department of Justice, and “are almost there.” SHPG/4502:JP Chances that the group of Takeda minority … Read Morefeatured

Peritoneal Divestiture Also Required in Fresenius Acquisition of NxStage

The review by the U.S. Federal Trade Commission of the acquisition of NxStage by Fresenius is on track and moving forward, according to a source familiar with the matter.featured

Fresenius Continues to Advance NxStage Acquisition

Fresenius is on track to close its acquisition of NxStage on the timeline that the parties have indicated to the market, CTFN has learned.featured

Five Essentials from CTFN This Week

A decision in the Aetna/CVS Health merger is likely to come in the next three to six weeks, according to a former assistant section chief in the healthcare and consumer products section within the Department of Justice’s antitrust division. More here … U.S. state insurance department reviews of AXA’s $15.3 billion acquisition of Bermuda-based XL … Read Morefeatured

Implications of Bloodlines Sale for FTC Review of NxStage/Fresenius

NxStage agreed on July 10 to sell its bloodlines business, operated under the Medisystems name, to B. Braun Medical, subject to approval by the U.S. Federal Trade Commission and thefeatured

Four Essentials from CTFN This Week

Industrial gas giants Linde and Praxair are in discussions with Latin American regulators for the sale of the overlapping assets that will need to be divested to gain clearance for their planned merger. More here … As the pleading cycle for the Tribune/Sinclair merger comes to a close, it appears unlikely the Federal Communications Commission … Read Morefeatured

NxStage/Fresenius Review Lingers at FTC

Fresenius and NxStage are several months into a timing agreement with the Federal Trade Commission as the agency continues its review of the companies’ pendingfeatured

Three Essentials from CTFN This Week

The regulatory overhaul leading to the creation of China’s State Administration for Market Regulation (SAMR) is affecting ongoing merger reviews,featured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.